首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1736708

2026 年至 2032 年血球容积比检测设备市场（依产品、应用、最终用户及地区）

Hematocrit Test Devices Market By Product, Application, End-User, & Region for 2026-2032

出版日期: 2025年05月07日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

血球比容检测设备市场评估-2026-2032

自动分析仪和携带式照护现场工具等技术的发展将透过提供更快、更准确、更便利的检测来推动市场成长。因此，技术进步将倍增市场规模的成长，到2024年将达到43.6亿美元，到2032年将达到57.8亿美元。

医疗保健支出的不断增长，推动了对诊断工具的更多投资，加速了技术创新和血球比容检测设备的普及。因此，由于医疗保健支出的不断增长，预计2026年至2032年期间该市场的复合年增长率将达到3.60%。

血球比容检测设备市场定义/概述

血球比容测试仪器是诊断医学中必不可少的工具，用于测量红血球 (RBC) 在人体总血容量中的百分比。此测量值称为血球比容值，它能够为各种健康状况提供宝贵的见解，从发烧等轻微疾病到贫血和癌症等严重，不一而足。血球比容测试计算的是红血球体积与总血容量的比率。偏离正常范围通常表示存在影响红血球生成或寿命的疾病。

进行血球容积比检测需要采集少量血液样本，通常透过指尖采血或静脉穿刺。然后将样本放入特製试管中，放入离心机中旋转，离心机根据血液成分的密度进行分离，使红血球沉淀到试管底部。自动化分析仪和照护现场血球容积比检测设备推动了这个检测过程，使其更快、更准确、更方便。这些设备越来越多地与数位技术融合，使检测更加高效可靠。血球容积比检测设备在早期诊断和监测中发挥关键作用，帮助医护人员管理各种健康状况并改善患者预后。

血球容积比测试需求的不断增长如何推动血球容积比测试设备市场的成长？

贫血、红血球增多症和其他血液疾病的病例正在增加，对血球比容测试的需求也随之增加，以便早期诊断和有效的疾病管理。 WHO（2022）报告称，非传染性疾病每年导致 4,100 万人死亡，占全球整体的 74%。 CDC（2021）指出，1.33 亿美国人患有至少一种慢性病。根据 NIH（2022）的数据，自 2020 年以来，全球糖尿病盛行率增加了 8.5%。不断增长的老龄人口容易患贫血和各种血液疾病，定期进行血细胞比容测试对于监测健康和预防併发症至关重要。随着老龄人口的增长，预计对这些测试和设备的需求将会增加。根据联合国世界人口展望，2022 年 65 岁以上人口到 2050 年将达到 16 亿。 WHO 估计，80% 的老年人口患有至少一种慢性疾病。欧盟报告称，2020年至2022年间，老年人照护方面的医疗支出将增加15%。

美国红十字会（2022年）报告称，美国每天需要约29,000个红血球。世界卫生组织报告称，全球捐血需求将增加6%。急诊室的输血程序将增加18%。

血球比容检测设备（包括自动分析仪和携带式照护现场设备）的进步透过提供更快、更准确和更便捷的检测解决方案，推动了市场成长。自动化和数位技术的整合进一步提高了检测效率和可靠性，使这些设备在医疗保健领域的价值日益提升。与 2020 年相比，2022 年 FDA核准的照护现场设备将增加 28%。美国国立卫生研究院 (NIH) 报告称，2020 年至 2023 年 POC 检测市场的复合年增长率为 12.3%。 2020 年至 2022 年，POC 检测的健保报销将增加 34%。世界反兴奋剂机构 (2022)：运动员血液检测将增加 15%。奥林匹克委员会 (2021) 对 85% 的耐力运动实施强制性血球比容监测。根据运动医学会的数据，到 2022 年，运动医学市场将达到 72 亿美元。

高昂的检测成本将如何阻碍血球容积比检测设备市场的成长？

血球比容检测以及其他诊断程序的成本可能很高，尤其是在开发中国家。这限制了那些无法负担检测费用的人获得检测的机会，凸显了对更实惠的诊断方案的需求，以扩大检测管道。根据美国国立卫生研究院 (NIH) (2022) 的数据，从 2020 年到 2022 年，医疗设备研发成本增加了 32%。 FDA 报告称，2022 年新型诊断设备的平均开发成本达到 3,100 万美元。医疗技术协会 (2021) 指出，45% 的小型医疗设备公司将高昂的研发成本视为成长的主要障碍。

许多地区，特别是开发中国家，无法充分获得医疗设施、诊断实验室和血库。这限制了血球容积比检测服务的普及，尤其是在农村和服务欠缺地区。世界卫生组织（2022 年）报告称，全球 47% 的人口无法获得基本的诊断服务。世界银行报告称，低收入国家只有 38% 的医疗机构拥有基本的诊断设备。联合国儿童基金会（2023 年）指出，32 亿人无法获得体外诊断检测。农村和服务欠缺地区有限的医疗基础设施阻碍了血球比容检测的普及。为了应对这项挑战并支持更广泛地进行检测，扩大医疗基础设施和改善诊断服务覆盖率的议程至关重要。

The development of advanced devices, including automated analyzers and portable point-of-care tools, enhances market growth by offering faster, more accurate, and convenient testing. Thus, the technological advancements surge the growth of market size surpassing USD 4.36 Billion in 2024 to reach the valuation of USD 5.78 Billion by 2032.

Rising healthcare expenditure supports greater investment in diagnostic tools, accelerating the innovation and adoption of hematocrit test devices. Thus, the increasing healthcare expenditure enables the market to grow at a CAGR of 3.60% from 2026 to 2032.

Hematocrit Test Devices Market: Definition/ Overview

Hematocrit test devices are essential tools in diagnostic medicine, used to measure the proportion of red blood cells (RBCs) in a person's total blood volume. This measurement, known as hematocrit, provides valuable insights into various health conditions, from mild ailments like fever to more serious diseases such as anemia or cancer. A hematocrit test calculates the ratio of RBC volume to total blood volume, with deviations from normal ranges often indicating conditions that affect red blood cell production or lifespan.

To perform a hematocrit test, a small blood sample is collected, usually through a finger prick or venipuncture. The sample is then placed in a specialized tube and spun in a centrifuge, which separates the blood components by density, allowing the red blood cells to settle at the bottom of the tube. Automated analyzers and point-of-care hematocrit test devices have advanced this process, making it faster, more accurate, and more convenient. These devices are increasingly integrated with digital technologies, improving the efficiency and reliability of testing. Hematocrit test devices play a crucial role in early diagnosis and monitoring, supporting healthcare providers in managing various health conditions and enhancing patient outcomes.

How the Increasing Demand for Hematocrit Testing Surge the Growth of Hematocrit Test Devices Market?

Growing cases of anemia, polycythemia, and other blood disorders are increasing the demand for hematocrit testing for early diagnosis and effective disease management. WHO (2022) reported that non-communicable diseases cause 41 million deaths each year, equivalent to 74% of all deaths globally. CDC (2021) stated that 133 million Americans have at least one chronic disease. According to NIH (2022), diabetes prevalence increased by 8.5% globally since 2020. The increasing geriatric population is more prone to anemia and various blood disorders, making regular hematocrit testing essential for monitoring health and preventing complications. With a growing elderly population, the demand for these tests and devices is expected to rise. UN World Population Prospects 2022 people aged 65+ will reach 1.6 billion by 2050. WHO estimated that 80% of older adults have at least one chronic condition. The European Union reported a 15% increase in healthcare spending for elderly care from 2020-2022.

American Red Cross (2022) nearly 29,000 units of red blood cells are needed daily in the U.S. WHO reported a 6% increase in blood donation demands globally. Blood transfusion procedures increased by 18% in emergency departments.

Advancements in hematocrit test devices, including automated analyzers and portable point-of-care units, are driving market growth by offering faster, more accurate, and convenient testing solutions. The integration of automation and digital technologies further enhances testing efficiency and reliability, making these devices increasingly valuable in healthcare. FDA approved 28% more point-of-care devices in 2022 compared to 2020. NIH reported that the POC testing market grew at 12.3% CAGR from 2020-2023. Medicare claims for POC testing increased by 34% between 2020-2022. World Anti-Doping Agency (2022): 15% increase in blood testing among athletes. The Olympic Committee (2021) implemented mandatory hematocrit monitoring for 85% of endurance sports. According to the Sports Medicine Association, the sports medicine market will reach $7.2 billion by 2022.

How does the High Testing Cost Impede the Growth of the Hematocrit Testing Device Market?

Hematocrit testing, along with other diagnostic procedures, can be costly, especially in developing countries. This limits access to testing for individuals with limited financial resources, highlighting the need for more affordable diagnostic options to broaden access. According to NIH (2022), medical device R&D costs increased by 32% from 2020-2022. FDA reported that the average development cost for new diagnostic devices reached USD 31 Million in 2022. Medical Technology Association (2021) noted that 45% of small device companies cited high R&D costs as their primary growth barrier

In many regions, particularly in developing countries, access to healthcare facilities, diagnostic laboratories, and blood banks is insufficient. This restricts the availability of hematocrit testing services, especially in rural and underserved areas. WHO (2022) reported that 47% of the global population lacks access to essential diagnostic services. World Bank only 38% of healthcare facilities in low-income countries have basic diagnostic equipment. UNICEF (2023) stated that 3.2 billion people lack access to in-vitro diagnostic testing. Limited healthcare infrastructure in rural and underserved areas hinders the accessibility of hematocrit testing. Efforts to expand healthcare infrastructure and improve diagnostic service access are essential to address this challenge and support broader testing availability.

Category-Wise Acumens

How the Compact and Portable Design Surge the Growth of Hematocrit Test Meter Segment?

The hematocrit test meter segment dominates the Hematocrit Test Devices Market, owing to its compact and portable design that makes it well-suited for point-of-care testing across diverse healthcare settings, including primary care, clinics, and home healthcare. These meters are user-friendly, highly transportable, and cost-effective, offering a practical solution for settings where access to larger, stationary equipment is limited. Their rapid result delivery enables healthcare providers to diagnose and treat conditions promptly, which is especially beneficial in urgent care scenarios.

To address the rising demand for point-of-care testing, manufacturers are prioritizing the development of smaller and even more portable hematocrit test meters, enhancing their usability in various environments. Additionally, the integration of these devices with digital health platforms facilitates remote monitoring and data analysis, allowing healthcare professionals to track patients' hematocrit levels and overall health remotely. Ongoing advancements in automation are further improving the functionality of hematocrit test meters, increasing their testing throughput and accuracy. This combination of portability, digital integration, and automation makes hematocrit test meters a key growth driver in the Hematocrit Test Devices Market, as they support efficient, accessible, and reliable diagnostics.

How does the Deficiency of Red Blood Cells and Monitoring for Effective Treatment Foster the Growth of the Anemia Segment?

The anemia segment is dominant in the Hematocrit Test Devices Market owing to the critical role of hematocrit testing in diagnosing and managing anemia. Anemia, characterized by a deficiency of red blood cells or hemoglobin, is a widespread condition requiring timely detection and ongoing monitoring for effective treatment. Hematocrit tests enable early identification of anemia, which is essential for initiating prompt treatment to prevent further health complications.

Monitoring hematocrit levels also allows healthcare providers to track the effectiveness of anemia treatments over time, ensuring that treatment plans are achieving the desired outcomes. Beyond anemia, hematocrit testing is expanding into applications like assessing hydration status, evaluating kidney function, and identifying nutritional deficiencies, broadening the utility of these devices. Additionally, the shift toward personalized medicine has further strengthened demand in the anemia segment. Hematocrit tests can support tailored treatment plans by offering insight into an individual's unique health needs, enabling clinicians to adjust treatments accordingly.

Country/Region-wise Acumens

How the Advanced Healthcare Infrastructure & High Healthcare Spending Hematocrit Test Devices Market in North America?

North America substantially dominates the Hematocrit Test Devices Market driven by the region's benefits from a robust healthcare infrastructure, featuring advanced diagnostic facilities and a highly skilled healthcare workforce. U.S. healthcare spending reached USD 4.3 Trillion in 2021. American Hospital Association (2022) reported 6,093 hospitals with advanced diagnostic facilities. Healthcare spending per capita in the U.S. increased by 9.7% from 2020-2022.

The increasing prevalence of chronic diseases such as diabetes, cardiovascular conditions, and kidney disorders drives the need for regular blood tests, including hematocrit testing, to support effective management and treatment. CDC (2022) reported that 6 in 10 U.S. adults have a chronic disease, with 4 in 10 having multiple conditions. American Cancer Society (2021) estimated 1.9 million new cancer cases, require regular blood monitoring. NIH (2023) data showed that anemia affects approximately 5.6% of the U.S. population, with higher rates in the elderly and women.

FDA approved 37% more hematology devices in 2022 compared to 2020. The U.S. medical device industry invested $22.4 billion in R&D. Clinical trials for hematology devices increased by 28% between 2020-2023.

How Economic Growth and Increasing Healthcare Investment Surge the Growth of Hematocrit Test Devices Market in Asia Pacific?

Asia Pacific is anticipated to witness the fastest growth in the Hematocrit Test Devices Market during the forecast period owing to the rapid economic growth in countries like China, India, and South Korea is leading to increased healthcare spending and improved healthcare infrastructure. China's healthcare spending grew by 12.8% to reach USD 1.1 Trillion in 2022 (National Bureau of Statistics of China). India increased its healthcare budget by 137% between 2020-2023. Southeast Asian healthcare infrastructure investments reached USD 28.5 Billion in 2022.

The increasing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and anemia is driving the demand for diagnostic tools like hematocrit test devices. WHO Western Pacific Region (2022) reported 1.9 billion people with 35% above the age of 50. China CDC (2021) documented 116 million diabetes cases requiring regular blood monitoring. Indian Council of Medical Research (2022) reported a 38% increase in blood disorder cases. Thailand welcomed 3.5 million medical tourists in 2022. Singapore's medical tourism revenue grew by 15% annually from 2020-2022. South Korea reported a 25% increase in international patients for medical procedures.

Competitive Landscape

The Hematocrit Test Devices Market is characterized by a mix of established global players and emerging regional companies. Key players in this market are continuously innovating to develop advanced devices and expand their market reach.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Hematocrit Test Devices Market include Sysmex Corporation, Abbott Laboratories, Hoffmann-La Roche Ltd., Siemens AG, Beckman Coulter, Nihon Kohden Corporation, Boule Diagnostics AB, EKF Diagnostics, Nova Biomedical, HORIBA, Ltd.

Latest Developments

In March 2024, Siemens Healthineers announced the launch of its next-generation automated hematology analyzer, with integrated hematocrit testing capabilities that promise 30% faster findings.

In April 2020, Nova Biomedical announced the launch of the State EMS Basic blood testing system for ambulance and emergency care in CE mark countries.

1 INTRODUCTION OF GLOBAL HEMATOCRIT TEST DEVICES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL HEMATOCRIT TEST DEVICES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY PRODUCT

5.1 Overview
5.2 Hematocrit Test Meter
5.3 Hematocrit Test Analyzer
5.4 Reagents and Consumables

6 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY APPLICATION

6.1 Overview
6.2 Anemia
6.3 Polycythemia Vera
6.4 Congenital Heart Diseases
6.5 Others

7 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY END-USER

7.1 Overview
7.2 Hospitals & clinics
7.3 Diagnostic Centers
7.4 Others

8 GLOBAL HEMATOCRIT TEST DEVICES MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL HEMATOCRIT TEST DEVICES MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Sysmex Corporation
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Abbott Laboratories
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 F. Hoffmann-La Roche Ltd.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Siemens AG
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Beckman Coulter
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Nihon Kohden Corporation
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Boule Diagnosis AB
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 EKF Diagnostics
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Nova Biomedical
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 HORIBA Ltd.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments

11 Appendix

11.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

2026 年至 2032 年血球容积比检测设备市场（依产品、应用、最终用户及地区）

Hematocrit Test Devices Market By Product, Application, End-User, & Region for 2026-2032

血球比容检测设备市场评估-2026-2032

血球容积比测试需求的不断增长如何推动血球容积比测试设备市场的成长？

高昂的检测成本将如何阻碍血球容积比检测设备市场的成长？

目录

第一章 全球血球容积比检测设备市场介绍

第二章执行摘要

第三章：已验证的市场研究调查方法

第四章。全球血球比容检测仪器市场展望

第五章全球血球容积比检测仪器市场（依产品）

第六章全球血球容积比检测仪器市场（依应用）

第七章全球血球容积比检测仪器市场（依最终用户）

8. 全球血球容积比检测仪器市场（按地区）

第九章全球血球容积比检测设备市场的竞争格局

第十章 公司简介

第十一章 附录

Hematocrit Test Devices Market Valuation - 2026-2032